辽宁成大生物股份有限公司 2025年第三季度报告
Zheng Quan Ri Bao·2025-10-29 22:56

Core Viewpoint - The company plans to use up to RMB 700 million of idle raised funds for cash management, ensuring that it does not affect the implementation of investment projects and the safety of the raised funds [9][25][27] Financial Data - The financial reports for the third quarter are unaudited, and the company has confirmed the accuracy and completeness of the financial information [3][2] - As of September 30, 2025, the company has a repurchase account holding 5,199,548 shares, accounting for 1.25% of the total share capital [5] Fund Management - The company will use the idle funds to purchase high-security, liquid investment products from qualified financial institutions, including but not limited to large deposits, structured deposits, and cash management products [9][15] - The investment period for the cash management is valid for 12 months from the board's approval date, and the funds can be rolled over within this limit [16][20] Approval Process - The board of directors has authorized the management to make investment decisions within the approved limits and duration, including selecting financial institutions and signing relevant contracts [10][25] - The company’s sponsor, CITIC Securities, has provided a clear verification opinion on this matter [11][27] Investment Purpose - The purpose of using idle funds for cash management is to enhance the efficiency of fund utilization and increase company returns while ensuring the normal operation of investment projects [14][20] Risk Control Measures - The company will implement strict risk control measures, including regular monitoring of investment products and maintaining confidentiality regarding financial transactions [22][24]